Suliman named CEO of ReCode
Plus Cohen leaving Adaptive as CFO and updates from iTeos, Sorrento and more
Former Alector Inc. (NASDAQ:ALEC) President and COO Shehnaaz Suliman will take over ReCode Therapeutics’ CEO post from David Lockhart, who will become CSO while remaining president and a director. ReCode, which is pairing RNA therapeutics for genetic respiratory diseases with an organ-specific lipid nanoparticle delivery technology, raised $80 million in a 2020 series A round led by OrbiMed and Colt Ventures. Suliman also joins the board.
Chad Cohen has resigned as CFO of Adaptive Biotechnologies Corp. (NASDAQ:ADPT), effective Feb. 15. The adaptive immune company also announced preliminary 2021 revenue of $153-$154 million, in line with the Street estimate, according to FactSet. Principal Accounting Officer Kyle Piskel will serve as interim CFO; Cohen will remain as an adviser. Shares fell 5% on Monday to $21.95...